Latin America Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Latin America Human Insulin Drugs Market is Segmented Into Product Type (Insulin Drugs, Oral Anti-Diabetes Drugs, And Non-Insulin Injectable Drugs) and Geography. The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Latin America Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Latin America Diabetes Care Drugs Market Size

View Global Report
Latin America Diabetes Care Drugs Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 4.87 Billion
Market Size (2030) USD 5.78 Billion
CAGR (2025 - 2030) 3.48 %

Major Players

Latin America Diabetes Care Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Latin America Diabetes Care Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Latin America Diabetes Care Drugs Market Analysis

The Latin America Diabetes Care Drugs Market size is estimated at USD 4.87 billion in 2025, and is expected to reach USD 5.78 billion by 2030, at a CAGR of 3.48% during the forecast period (2025-2030).

The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, is acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, close to 10% of the total population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, and they accounted for close to 90% of the total diabetic population in 2021.

Based on drugs, the insulin segment holds a significant share in the market. Over 100 million people around the world need insulin, including all the people suffering from Type-1 diabetes and between 10% and 25% of people with Type-2 diabetes. Production of insulin is very complex, and there are very few companies in the market that manufacture insulin. Due to this, there is high competition between these manufacturers, who always strive to meet the patient's needs to supply the best-quality insulin.

Latin America Diabetes Care Drugs Industry Overview

The Latin American diabetes care drugs market includes several established global and local players. In Latin America, only a few players significantly share the need for branded drugs. However, the number of players for generic drugs is high, including several local ones. Novo Nordisk holds the largest share in the Latin American diabetes care drug market. Branded drugs from Eli Lilly and Boehringer Ingelheim Alliance are expected to record a high CAGR of more than 15% in the forecast period.

Latin America Diabetes Care Drugs Market Leaders

  1. Novo Nordisk

  2. Sanofi

  3. Eli Lilly

  4. AstraZeneca

  5. Boehringer Ingelheim

  6. *Disclaimer: Major Players sorted in no particular order
Latin America Diabetes Care Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Latin America Diabetes Care Drugs Market News

  • September 2023: Anvisa, Brazil's federal health regulator, approved tirzepatide. This injectable medication is designed to enhance blood sugar management in adults diagnosed with Type 2 diabetes. Manufactured by the renowned U.S. pharmaceutical company Eli Lilly, tirzepatide is marketed under the brand name Mounjaro. 
  • March 2022: Oramed announced ORMD-0801 (a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule with the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets. Oramed also develops an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).

Latin America Diabetes Care Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Type
    • 5.1.1 Insulin Drugs
    • 5.1.1.1 Traditional Human Insulins
    • 5.1.1.1.1 Humilin
    • 5.1.1.1.2 Novolin
    • 5.1.1.1.3 Insuman
    • 5.1.1.2 Basal Insulin or Long-acting Insulin
    • 5.1.1.2.1 Lantus
    • 5.1.1.2.2 Levemir
    • 5.1.1.2.3 Tresiba
    • 5.1.1.2.4 Toujeo
    • 5.1.1.2.5 Basaglar
    • 5.1.1.3 Bolus Insulin or Fast-acting Insulin
    • 5.1.1.3.1 Novolog/NovoRapid
    • 5.1.1.3.2 Humalog
    • 5.1.1.3.3 Apidra
    • 5.1.1.3.4 FIASP
    • 5.1.1.3.5 Admelog
    • 5.1.1.4 Insulin Combinations
    • 5.1.1.4.1 NovoMix
    • 5.1.1.4.2 Ryzodeg
    • 5.1.1.4.3 Xultophy
    • 5.1.1.4.4 Soliqua/Suliqua
    • 5.1.1.5 Biosimilar Insulin
    • 5.1.1.5.1 Insulin Glargine
    • 5.1.1.5.2 Other Biosimilar Insulins
    • 5.1.2 Oral Anti-Diabetes Drugs
    • 5.1.2.1 Biguanides (Metformin)
    • 5.1.2.2 Alpha - Glucosidase Inhibitors
    • 5.1.2.3 Dopamine D2 Receptor Agonist (Bromocriptin)
    • 5.1.2.4 Sodium - Glucose Cotransport -2 (SGLT-2) Inhibitor
    • 5.1.2.4.1 Invokana (Canagliflozin)
    • 5.1.2.4.2 Jardiance (Empagliflozin)
    • 5.1.2.4.3 Farxiga/Forxiga (Dapagliflozin)
    • 5.1.2.4.4 Suglat (Ipragliflozin)
    • 5.1.2.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
    • 5.1.2.5.1 Sitagliptin (Januvia)
    • 5.1.2.5.2 Saxagliptin (Onglyza)
    • 5.1.2.5.3 Linagliptin (Tradjenta)
    • 5.1.2.5.4 Alogliptin (Vipidia/Nesina)
    • 5.1.2.5.5 Vildagliptin (Galvus)
    • 5.1.2.6 Sulfonylureas
    • 5.1.2.7 Meglitinide
    • 5.1.2.8 Janumet (Sitagliptin and Metformin HCl)
    • 5.1.3 Non-insulin Injectable Drugs
    • 5.1.3.1 GLP-1 Receptor Agonists
    • 5.1.3.1.1 Victoza (Liraglutide)
    • 5.1.3.1.2 Byetta (Exenatide)
    • 5.1.3.1.3 Bydureon (Exenatide)
    • 5.1.3.1.4 Trulicity (Dulaglutide)
    • 5.1.3.1.5 Lyxumia (Lixisenatide)
    • 5.1.3.1.6 Janumet (Sitagliptin and Metformin HCl)
    • 5.1.3.2 Amylin Analogue
    • 5.1.3.2.1 Symlin (Pramlintide)
  • 5.2 Geography
    • 5.2.1 Brazil
    • 5.2.2 Mexico
    • 5.2.3 Rest of Latin America

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Sanofi
    • 7.1.3 Eli Lilly
    • 7.1.4 Takeda
    • 7.1.5 Pfizer
    • 7.1.6 Janssen Pharmaceuticals
    • 7.1.7 Astellas
    • 7.1.8 Boehringer Ingelheim
    • 7.1.9 Merck and Co.
    • 7.1.10 AstraZeneca
    • 7.1.11 Bristol Myers Squibb
    • 7.1.12 Novartis
  • *List Not Exhaustive
  • 7.2 Company Share Analysis
    • 7.2.1 Novo Nordisk
    • 7.2.2 Sanofi
    • 7.2.3 Eli Lilly
    • 7.2.4 AstraZeneca
    • 7.2.5 Astellas
    • 7.2.6 Janssen Pharmaceuticals
    • 7.2.7 Merck and Co.
    • 7.2.8 Other Companies

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents. **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Latin America Diabetes Care Drugs Industry Segmentation

Controlling blood sugar through diet, oral medication, or insulin is the main treatment. Regular screening for complications is also required. Latin America, diabetes care drugs market, is segmented into product type (insulin drugs, oral anti-diabetes drugs, and non-insulin injectable drugs) and geography. The report offers the value (in USD) and volume (in units) for the above segments. 

Type Insulin Drugs Traditional Human Insulins Humilin
Novolin
Insuman
Basal Insulin or Long-acting Insulin Lantus
Levemir
Tresiba
Toujeo
Basaglar
Bolus Insulin or Fast-acting Insulin Novolog/NovoRapid
Humalog
Apidra
FIASP
Admelog
Insulin Combinations NovoMix
Ryzodeg
Xultophy
Soliqua/Suliqua
Biosimilar Insulin Insulin Glargine
Other Biosimilar Insulins
Oral Anti-Diabetes Drugs Biguanides (Metformin)
Alpha - Glucosidase Inhibitors
Dopamine D2 Receptor Agonist (Bromocriptin)
Sodium - Glucose Cotransport -2 (SGLT-2) Inhibitor Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors Sitagliptin (Januvia)
Saxagliptin (Onglyza)
Linagliptin (Tradjenta)
Alogliptin (Vipidia/Nesina)
Vildagliptin (Galvus)
Sulfonylureas
Meglitinide
Janumet (Sitagliptin and Metformin HCl)
Non-insulin Injectable Drugs GLP-1 Receptor Agonists Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Janumet (Sitagliptin and Metformin HCl)
Amylin Analogue Symlin (Pramlintide)
Geography Brazil
Mexico
Rest of Latin America
Need A Different Region or Segment?
Customize Now

Latin America Diabetes Care Drugs Market Research FAQs

How big is the Latin America Diabetes Care Drugs Market?

The Latin America Diabetes Care Drugs Market size is expected to reach USD 4.87 billion in 2025 and grow at a CAGR of 3.48% to reach USD 5.78 billion by 2030.

What is the current Latin America Diabetes Care Drugs Market size?

In 2025, the Latin America Diabetes Care Drugs Market size is expected to reach USD 4.87 billion.

Who are the key players in Latin America Diabetes Care Drugs Market?

Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca and Boehringer Ingelheim are the major companies operating in the Latin America Diabetes Care Drugs Market.

What years does this Latin America Diabetes Care Drugs Market cover, and what was the market size in 2024?

In 2024, the Latin America Diabetes Care Drugs Market size was estimated at USD 4.70 billion. The report covers the Latin America Diabetes Care Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Latin America Diabetes Care Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Latin America Diabetes Care Drugs Industry Report

Statistics for the 2025 Latin America Diabetes Care Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Latin America Diabetes Care Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.